<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <title>Using a double binding antigen assay to detect and measure SARS-CoV-2 antibodies</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />

    <link rel="apple-touch-icon" sizes="180x180" href="/img/favicon/apple-touch-icon.png">
    <link rel="icon" type="image/png" sizes="32x32" href="/img/favicon/favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="/img/favicon/favicon-16x16.png">
    <link rel="manifest" href="/img/favicon/site.webmanifest">
    <link rel="mask-icon" href="/img/favicon/safari-pinned-tab.svg" color="#5bbad5">
    <link rel="shortcut icon" href="/img/favicon/favicon.ico">

  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@400;700&display=swap" rel="stylesheet">
  <link href="/assets/css/style.css" rel="stylesheet">
  
  <meta property="og:title" content="Outbreak Data Analysis Platform" />
  <meta property="og:type" content="website" />
  <meta property="og:url" content="https://odap.ac.uk" />
  <meta property="og:image" content="https://odap.ac.uk/img/logo/logo.svg" />
  <meta property="og:description" content="Outbreak Data Analysis Platform." />
  <meta name="twitter:card" content="summary" />
  <meta name="twitter:site" content="" />
  <meta name="twitter:creator" content="" />
</head>
<body class='page page-outputs-single' >
  <div id="main-menu-mobile" class="main-menu-mobile">
  
  <ul>
    
    <li class="">
      <a href="/analysis-platform">Analysis Platform</a>
    </li>
    
    <li class="">
      <a href="/outputs/">Outputs</a>
    </li>
    
    <li class="">
      <a href="/reports/">Live Reports</a>
    </li>
    
    <li class="">
      <a href="/jobs/">Jobs</a>
    </li>
    
    <li class="">
      <a href="/sample_access/">Access requests</a>
    </li>
    
    <li class="">
      <a href="/setup/">Site set-up</a>
    </li>
    
  </ul>
</div>
  <div id="wrapper" class="wrapper">
    <div class='header'>
  <div class="container">
    <div class="logo">
      <a href="/"><img height="36px" alt="ODAP" src="/img/logo/logo.svg" /></a>
    </div>
    <div class="logo-mobile">
      <a href="/"><img alt="ODAP" src="/img/logo/logo.svg" /></a>
    </div>
    <div id="main-menu" class="main-menu">
  
  <ul>
    
    <li class="">
      <a href="/analysis-platform">Analysis Platform</a>
    </li>
    
    <li class="">
      <a href="/outputs/">Outputs</a>
    </li>
    
    <li class="">
      <a href="/reports/">Live Reports</a>
    </li>
    
    <li class="">
      <a href="/jobs/">Jobs</a>
    </li>
    
    <li class="">
      <a href="/sample_access/">Access requests</a>
    </li>
    
    <li class="">
      <a href="/setup/">Site set-up</a>
    </li>
    
  </ul>
</div>

    <button id="toggle-main-menu-mobile" class="hamburger hamburger--slider" type="button" aria-label="Mobile Menu">
  <span class="hamburger-box">
    <span class="hamburger-inner"></span>
  </span>
</button>
  </div>
</div>
    <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script>

<div class="container pb-6 pt-6 pt-md-10 pb-md-10">
  <div class="row justify-content-start">
    <div class="col-12 col-md-8">
      <div class="output output-single">
        <h1 class="title">Using a double binding antigen assay to detect and measure SARS-CoV-2 antibodies</h1>
        <div class="altmetric-embed" data-badge-type="donut" data-doi="https://doi.org/10.1016/j.jviromet.2022.114475"></div>
        <div class="content"><p><a href="https://doi.org/10.1016/j.jviromet.2022.114475">Journal of Virological Methods, April 2022</a></p>

<p>Accurate and sensitive detection of antibody to SARS-CoV-2 remains an essential component of the pandemic response. 
Measuring antibody that predicts neutralising activity and the vaccine response is an absolute requirement for laboratory-based confirmatory and reference activity.
The viral receptor binding domain (RBD) constitutes the prime target antigen for neutralising antibody. A hybrid double antigen binding assay (DABA) for anti-RBD showed a specificity of 100 % on 825 pre COVID-19 samples and a potential sensitivity of 99.6 % on 276 recovery samples, predicting quantitatively the presence of neutralising antibody determined by pseudo-type neutralization and by plaque reduction.</p>
</div>
      </div>
    </div>
  </div>
</div>
  </div>
  <div class="footer">
  <div class="container">
    <div class="row">
      <div class="col-12">
        <div class="footer-inner">
          <h3 class="footer-title">ODAP</h3>
          <ul>
            
            
            <li class="">
              <a href="/">Home</a>
            </li>
            
            <li class="">
              <a href="/privacy/">Privacy</a>
            </li>
            
          </ul>
        </div>
      </div>
    </div>
  </div>
</div>
  <div class="sub-footer">
  <div class="container">
    <div class="row">
      <div class="col-12">
        <div class="sub-footer-inner">
          
            <div class="social">
  
    <a href="https://twitter.com/ccpukstudy" target="blank"><img src="/img/social/twitter.svg" title="Twitter" alt="Twitter" /></a>
  
</div>

          
          
          <div class="copyright">Outbreak Data Analysis Platform</div>
          
        </div>
      </div>
    </div>
  </div>
</div>
  <script type="text/javascript" src="/assets/js/scripts.js"></script>
  
</body>
</html>
